Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluoro-donepezil
- Development stage
- Phase 1
- Lead developer
- Lianyungang Kanion
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fluoro-donepezil (also known as KNP01) is a small molecule acetylcholinesterase inhibitor (AChEI) developed by Jiangsu Kanion Pharmaceutical for the treatment of Alzheimer's disease. It is a fluorinated derivative of donepezil, a standard-of-care treatment for Alzheimer's. The incorporation of fluorine atoms into the donepezil scaffold is intended to optimize the drug's pharmacokinetic properties, potentially improving metabolic stability and brain permeability. Clinical development has progressed through Phase 1 trials in China, where it was evaluated for safety, tolerability, and pharmacokinetics in healthy elderly volunteers.
- Other names
- fluoro-donepezilfluorodonepezil氟多奈哌齐
02
Targets
Acetylcholinesterase
Beyond the preview
Go deeper on fluoro-donepezil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluoro-donepezil.